New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.60-0.45 (-3.73%)
At close: 04:00PM EST
11.60 0.00 (0.00%)
After hours: 04:31PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 440.57M
Enterprise value 324.39M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)23.21
Price/book (mrq)3.94
Enterprise value/revenue 18.62
Enterprise value/EBITDA -4.13

Trading information

Stock price history

Beta (5Y monthly) 1.53
52-week change 3-38.82%
S&P500 52-week change 314.07%
52-week high 322.24
52-week low 311.57
50-day moving average 314.27
200-day moving average 315.18

Share statistics

Avg vol (3-month) 3113.27k
Avg vol (10-day) 3135.5k
Shares outstanding 532.32M
Implied shares outstanding 6N/A
Float 821.35M
% held by insiders 116.33%
% held by institutions 157.62%
Shares short (30 Dec 2021) 42.29M
Short ratio (30 Dec 2021) 419.71
Short % of float (30 Dec 2021) 48.88%
Short % of shares outstanding (30 Dec 2021) 47.08%
Shares short (prior month 29 Nov 2021) 42.35M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin 0.00%
Operating margin (ttm)-455.05%

Management effectiveness

Return on assets (ttm)-32.84%
Return on equity (ttm)-64.66%

Income statement

Revenue (ttm)17.42M
Revenue per share (ttm)0.59
Quarterly revenue growth (yoy)-23.30%
Gross profit (ttm)-57.67M
EBITDA -78.62M
Net income avi to common (ttm)-79.1M
Diluted EPS (ttm)-2.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)123.42M
Total cash per share (mrq)3.82
Total debt (mrq)7.23M
Total debt/equity (mrq)6.46
Current ratio (mrq)7.64
Book value per share (mrq)3.47

Cash flow statement

Operating cash flow (ttm)-53.38M
Levered free cash flow (ttm)-33.79M